Clinical and Preclinical Development of a Recombinant Subunit Vaccine for Dengue

Date/Time: 07 January 2015, 12:00 PM - 1:00 PM
Speaker: Beth-Ann Griswold Coller, Ph.D.
Speaker Affiliation: Executive Director, Project Leader, Merck & Company
Venue: John A. Burns School of Medicine, Kaka’ako Campus, 651 Ilalo Street, MEB Auditorium (Room 315)

For more info: Cori Watanabe 808-692-1654
Description: Dr. Beth-Ann Coller Ph.D., Executive Director with Merck and Co., and former Senior Vice President for Research and Development at Hawaii Biotech, Inc., will present an overview of the most recent clinical and preclinical results for the Hawaii Biotech/Merck dengue vaccine candidate. Dr. Coller received her Ph.D. in 1993 from the University of Nebraska Medical Center, where she studied the molecular virology of picornaviruses. She then joined Hawaii Biotech where her research focused on development of recombinant subunit flavivirus vaccines. In 1999, Dr. Coller joined GlaxoSmithKline Biologicals in Rixensart Belgium where she was the project manager for the dengue vaccine project and led the Preclinical Virology Group which was responsible for preclinical development of all viral vaccine projects. In 2004 Dr. Coller rejoined Hawaii Biotech and was ultimately responsible for all Research and Development activities including the development of the HBI West Nile and dengue vaccines. In August 2010, with the Merck acquisition of the Hawaii Biotech dengue program, Dr. Coller joined Merck where she is currently leading the product development teams for dengue and other vaccine targets.
Additional Document:Click here to download